Delivery Order HHSN271201800001I-75N95025F00001
Ended Awarded Last action
- Contract number
- 75N95025F00001
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $922,304
Award facts
- Opportunity
-
- TORFPNIHNINDS2502 Solicitation number
- Contract value 36% obligated
-
- $922,304.36 Current, with exercised options
- $2,592,564.37 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
This federal contract award, valued at $2,592,564.37, was issued by the National Institute of Neurological Disorders and Stroke (NINDS) to Curia Global Inc. (doing business as Amri), a leading global contract development and manufacturing organization (CDMO). The award is for a Delivery Order under the Biomedical Prototype Network - Medicinal Chemistry Support Program for Therapeutic Development (BPN-MCSP-HIT) to support chemistry-related services, including hit-to-lead chemistry, for the Martin (Nuvonuro) program. No set-aside designation was used for this award. Curia has extensive experience supporting various National Institutes of Health (NIH) institutes and other federal agencies through prime and subcontract awards, focusing on therapeutic development initiatives in areas such as neurology, infectious diseases, and substance abuse. This contract award is part of Curia's broader work with the NIH to provide a wide range of pharmaceutical research and development services, from early-stage drug discovery through commercialization.
Quick answers
Who was awarded contract 75N95025F00001?
75N95025F00001 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on December 9, 2024.
How much is contract 75N95025F00001 worth?
The government has obligated $922,304 on 75N95025F00001. Its potential value, with all options, is $2,592,564.
Which agency awarded contract 75N95025F00001?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95025F00001, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95025F00001 an order under another contract?
Yes. 75N95025F00001 is a delivery order under HHSN271201800001I, an indefinite delivery contract.
Was contract 75N95025F00001 competed?
The extent of competition for 75N95025F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award